Passage BIO, Inc. (PASG)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

3.69 on 9 Oct 2026

1 buy2 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$45.52M

Free cash flow

$31.51M

Return on equity

-242.7%

Return on capital

-207.7%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
25 Jun 2026	Lynx1 Capital Management LP 10% owner	Bought	$206.10K	8.0%
8 Jan 2026	Chou William PRESIDENT AND CEO	Sold at will	$75.16K	38.5%
8 Jan 2026	Borthwick Kathleen CFO	Sold at will	$38.02K	27.6%
15 Sep 2025	Lynx1 Capital Management LP 10% owner	Bought	$83.18K	1.9%
12 Sep 2025	Lynx1 Capital Management LP 10% owner	Bought	$138.30K	3.3%
11 Sep 2025	Lynx1 Capital Management LP 10% owner	Bought	$2.26K	0.1%

25out of 100

Profitability 0

Financial strength 35

Growth n/a

Insiders 50

Strongest on insiders (50), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$206.10K

1 buy, 1 buyer

Sold

$113.18K

2 sales

Planned sales

under a 10b5-1 plan